Research Paper Volume 13, Issue 3 pp 3202—3217
GV1001 interacts with androgen receptor to inhibit prostate cell proliferation in benign prostatic hyperplasia by regulating expression of molecules related to epithelial-mesenchymal transition
Figure 2. Interaction of GV1001 with AR in prostatic epithelial and stromal cells. (A) RWPE-1 and WPMY-1 cells were pre-incubated for 1 h with an anti-AR antibody or an isotype control antibody, followed by FITC-conjugated GV1001 (GV-FITC) for 30 min. Then, GV1001-bound cells were analyzed by flow cytometry. The mean fluorescence intensity (MFI) of FITC in RWPE-1 and WPMY-1 cells is presented in the graph. ***p<0.001. (B) GV-FITC was applied to RWPE-1 and WPMY-1 cells, and internalization of the peptide was analyzed by fluorescence microscopy. Scale bar: 125 μm. (C) Interaction of GV1001 with AR was confirmed by co-immunoprecipitation.